 DiaMedica Therapeutics Inc NASDAQ: DMAC has announced positive interim results from its Phase 2 REDUX trial of DM199 in chronic kidney disease CKD. The trial is designed to evaluate the effect of DM199 across three cohorts, including African Americans AA, non-diabetic and hypertensive Cohort 1, n12, IgA Nephropathy IgAN Cohort 2, n16, and diabetic kidney disease DKD Cohort 3, n28. 